Kyverna Therapeutics(KYTX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results • Actively recruiting clinical trials in neurology and rheumatology with KYV-101 • No severe ICANS or CRS reported in first 36 autoimmune disease patients treated with KYV-101 • Received FDA RMAT Designation for KYV-101 for treatment of patients with Stiff-Person Syndrome • Received FDA RMAT Designation for KYV-101 for treatment of patients with Myasthenia Gravis • Reported clinical experience with f ...